表紙
市場調査レポート

真性赤血球増加症後骨髄線維症 (PPV-MF):パイプライン製品の分析

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251623
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
真性赤血球増加症後骨髄線維症 (PPV-MF):パイプライン製品の分析 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 102 Pages
概要

赤血病、脾腫性赤血球増加症および真性赤血球増加症としても知られる真性赤血球増加症(PC, PCV)は、骨髄が赤血球を過剰に作る骨髄増殖性の血液がんです。白血球および血小板の過剰生産も引き起こす可能性があります。症状には、心臓発作、心臓麻痺、深部静脈血栓症(DVT)、頭痛、集中力の欠如および疲労があります。この疾患は化学療法、輸血、移植および薬物療法によって制御できる場合があります。

当レポートでは、真性赤血球増加症後骨髄線維症 (PPV-MF)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

真性赤血球増加症後骨髄線維症 (PPV-MF) の概要

治療薬の開発

  • パイプライン製品の概要

真性赤血球増加症後骨髄線維症 (PPV-MF) :企業で開発中の治療薬

真性赤血球増加症後骨髄線維症 (PPV-MF) :パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品

真性赤血球増加症後骨髄線維症 (PPV-MF) :企業で開発中の製品

真性赤血球増加症後骨髄線維症 (PPV-MF) の治療薬開発に従事している企業

  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • JW Pharmaceutical Corporation
  • MEI Pharma, Inc.
  • 日本新薬
  • Novartis AG
  • Pfizer Inc.
  • Promedior, Inc.

真性赤血球増加症後骨髄線維症 (PPV-MF) :治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

真性赤血球増加症後骨髄線維症 (PPV-MF) :最近のパイプライン動向

真性赤血球増加症後骨髄線維症 (PPV-MF) :休止中のプロジェクト

真性赤血球増加症後骨髄線維症 (PPV-MF) :開発が中止された製品

真性赤血球増加症後骨髄線維症 (PPV-MF) :製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7902IDB

Summary

Global Markets Direct's, 'Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016', provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF)
  • The report reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics and enlists all their major and minor projects
  • The report assesses Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview
  • Therapeutics Development
    • Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development
    • Celgene Corporation
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Incyte Corporation
    • Italfarmaco S.p.A.
    • JW Pharmaceutical Corporation
    • MEI Pharma, Inc.
    • Nippon Shinyaku Co., Ltd.
    • Novartis AG
    • Pfizer Inc.
    • Promedior, Inc.
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CWP-291 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glasdegib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • idelalisib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LCL-161 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • momelotinib dihydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NS-018 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pomalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRM-151 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vismodegib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Recent Pipeline Updates
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Celgene Corporation, H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences, Inc., H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corporation, H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco S.p.A., H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma, Inc., H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pfizer Inc., H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics - Recent Pipeline Updates, H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H1 2016
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top